PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Eli Lilly and Company, Indianapolis, IN, 46285, USA. qu_yongming@lilly.com.\', \'Department of Data and Analytics, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, 46285, USA. qu_yongming@lilly.com.\', \'Eli Lilly and Company, Indianapolis, IN, 46285, USA.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1007/s43441-021-00297-6
?:hasPublicationType
?:journal
  • Therapeutic innovation & regulatory science
is ?:pmid of
?:pmid
?:pmid
  • 33983621
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
?:title
  • Implementation of ICH E9 (R1): A Few Points Learned During the COVID-19 Pandemic.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/33983621>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/33983621>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all